Metastatic Triple Negative Breast Cancer: The New Era of Thinking

Amrallah A. Mohammed; Mohamed A. Elbassuiony; Hanaa Rashied

doi:10.2478/fco-2018-0007

.blurhash-client-img { display: none !important; }

Metastatic Triple Negative Breast Cancer: The New Era of Thinking

Forum of Clinical Oncology

Volume 12 (2021): Issue 1 (May 2021)

By: Amrallah A. Mohammed, Mohamed A. Elbassuiony and Hanaa Rashied

Open Access

|May 2021

Abstract

The heterogeneity of triple negative breast cancer (TNBC) is reflected in a bizarre response to therapy. Although it is chemotherapy sensitive, the failure is the usual pathway either in local or distance status. With progression in Gene Expression Profile (GEP) and other molecular techniques, TNBC is divided into sub-types with unique pathways. In the current review, we are trying to highlight based on the molecular classification of TNBC and the management based on every type.

References

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumors. Nature. 2000; 406:747–752.
Search in Google Scholar Back to article
[Guideline] NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V 1.2016. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Version 3.2018 – October 25, 2018; Accessed: December 7, 2018.
Search in Google Scholar Back to article
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013: 31, 3997–4013.
Search in Google Scholar Back to article
Portha H, Jankowski C, Cortet M, Desmoulins I, Martin E, Lorgis V, Arnould L, Coutant C. [Nonmetastatic triple-negative breast cancer in 2016: Definitions and management]. Gynecol Obstet Fertil. 2016 Sep;44(9):492–504.
Search in Google Scholar Back to article
Prat A, Adamo B, Cheang MC. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013; 18:123–33.
Search in Google Scholar Back to article
Chandra D, Suresh P, Sinha R, Azam S, Batra U, Talwar V, Kumar K, Mehta A. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India. Asian Pac J Cancer Prev. 2016; 17:2995–9.
Search in Google Scholar Back to article
Jia Jin, Yu Gao, Jian Zhang, Leiping Wang, Biyun Wang, Jun Cao, Zhimin Shao, Zhonghua Wang. Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 2018; 18: 446.
Search in Google Scholar Back to article
Weigelt B, Ng CK, Shen R, Popova T, Schizas M, Natrajan R, et al. Metastatic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol. 2015; 28:340–351.
Search in Google Scholar Back to article
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Invest. 2011; 121:2750–67.
Search in Google Scholar Back to article
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014; 232:142–150.
Search in Google Scholar Back to article
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015; 21:1688–1698.
Search in Google Scholar Back to article
Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res. 2015; 17:43.
Search in Google Scholar Back to article
Valentin MD, da Silva SD, Privat M, Molecular insights on basal-like breast cancer. Breast Cancer Res Treat. 2012; 134(1):21–30.
Search in Google Scholar Back to article
Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, et al. TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902–1909.
Search in Google Scholar Back to article
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011 ; 15;10:1563–70.
Search in Google Scholar Back to article
Pfister K, Pipka JL, Chiang C, Liu Y, Clark RA, Keller R, et al. Todd Stukenberg. Identification of Drivers of Aneuploidy in Breast Tumors Cell Rep. 2018 ; 29; 23: 2758–2769.
Search in Google Scholar Back to article
Watkins JA, Irshad S, Grigoriadis A. Genomic scars as bio markers bio markers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014; 16:211.
Search in Google Scholar Back to article
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–533
Search in Google Scholar Back to article
Turner NC, Telli ML, Rugo HS, Mailliez M, J Ettl J, Grischke E-M, et al. Phase II ABRAZO: Talazoparib in gBRCA1/2 Mutation–Positive MBC.(Abstract 1007). Presented Jul 10 2017 ASCO Annual Meeting.
Search in Google Scholar Back to article
Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a ran domised phase 2 trial. Lancet Oncol 2014; 15:747–56.
Search in Google Scholar Back to article
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxoru bicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13–21.
Search in Google Scholar Back to article
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16:436–46.
Search in Google Scholar Back to article
Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, et al. Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials. 2016 Feb 3; 17:63.
Search in Google Scholar Back to article
Tutt A, Ellis P, Kilburn L, Cheang M, Bliss J, Dowsett M, Flanagan J. et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. (Abstract S3-01). Presented at December 11, 2014. SABCS 2014.
Search in Google Scholar Back to article
Choi JE, Kang SH, Lee SJ and Bae YK. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015; 22: 82–89.
Search in Google Scholar Back to article
McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer sub type. Ann Surg Oncol 2014; 21: 361–367.
Search in Google Scholar Back to article
Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013; 19:5505–12.
Search in Google Scholar Back to article
Traina TA, Miller K, Yardley DA, O’Shaughnessy J, Cortes J, Gradishar W, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol 2015; 33: S1003.
Search in Google Scholar Back to article
Adams S, Schmid P, Rugo HS, Loi S, Toppmeyer D, Awada A, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B (Abstract 1008.) Presented June 3, 2017 ASCO Annual Meeting.
Search in Google Scholar Back to article
Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015;7:309–16.
Search in Google Scholar Back to article
Kok M, Horlings HM, Vijver K. Russell N, Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial (Abstract LBA14) Presented Mar 31, 2017 ESMO Annual Meeting.
Search in Google Scholar Back to article
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, et al; Atezolizumab and NabPaclitaxel in Advanced Triple Negative Breast Cancer. N Engl J Med. 2018;379:2108–2121.
Search in Google Scholar Back to article
Yam C, Mani SA, Moulder SL. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. Oncologist. 2017; 22:1086–1093.
Search in Google Scholar Back to article
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615–23.
Search in Google Scholar Back to article
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92.
Search in Google Scholar Back to article
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 12; 377:914–23.
Search in Google Scholar Back to article
Berkey CS, Rosner B, Tamimi RM, Willett WC, Hickey M, Toriola A, et al. Body size from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 2017;162:139–149.
Search in Google Scholar Back to article
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al, Refinement of Triple Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11: e0157368.
Search in Google Scholar Back to article
Zhu Y, Zhao F, Li Z, Yu J. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 2018; 7; 10:2475–2488.
Search in Google Scholar Back to article
Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015; 26: 1904–1910.
Search in Google Scholar Back to article
Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, et al. Breast cancer molecular subtypes: from TNBC to QNBC Am J Cancer Res 2016;6:1864–1872.
Search in Google Scholar Back to article
Barton VN, D’Amato NC, Gordon MA. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer 2015; 6: 206–213.
Search in Google Scholar Back to article
Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl JMed 2008; 358:1409–1411.
Search in Google Scholar Back to article
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 2016; 27:1241–1248.
Search in Google Scholar Back to article
Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med. 2009; 15:842–4.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/fco-2018-0007 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 31 - 38

Submitted on: Dec 14, 2018

Accepted on: Apr 26, 2019

Published on: May 2, 2021

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Breast cancer,

triple-negative breast cancer,

Related subjects:

Haematology, oncology

© 2021 Amrallah A. Mohammed, Mohamed A. Elbassuiony, Hanaa Rashied, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 12 (2021): Issue 1 (May 2021)